Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Vertex

Why Vertex Pharmaceuticals Shares Are Falling

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday’s pre-market session after the company announced VX-880 Phase 1/2 has been placed on clinical hold by the FDA due to “a determination that there is insufficient information to support do

This Obscure Stock Has Outperformed Tech And EV Giants

This Obscure Stock Has Outperformed Tech And EV Giants

Vertex Energy Inc (NASDAQ: VTNR) has an average trading volume of over 2 million, so it is no slouch of a stock in terms of interest.

Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548. One trial looked at patients who had just received a bunionectomy (Correcting the deformity of toes & foot), the other in patients who received abdominoplasty (tummy tuck). Vertex said that within 48 hours of surgery,…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Well played: Cause for celebration as cystic fibrosis drug added to the PBS

Without PBS subsidy, around 1,900 Australians would be up for more than $250,000 a year to access the CF drug.

Newcastle Herald

What's Going On With Vertex Energy Shares Today?

Vertex Energy Inc (NASDAQ: VTNR) is trading higher on above-average volume Thursday as oil prices gain following the collapse of Russia-Ukraine ceasefire talks.

Vertex Clocks 12% Revenue Growth In Q4 Backed By ARR, NRR Momentum; Issues FY22 Guidance Above Consensus

Vertex Inc (NASDAQ:VERX) reported fourth-quarter FY21 revenue growth of 12.2% year-on-year to $111.7 million, beating the consensus of $109.2 million. Software subscription revenues rose 11.1% Y/Y to $93.3 million, and Cloud revenues increased 38.9% Y/Y to $34.7 million. Drivers: Annual Recurring Revenue rose 17% Y/Y to $370.2 million. The Average Annual Revenue per customer…

Vertex: Q4 Earnings Insights

Vertex (NASDAQ:VERX) reported its Q4 earnings results on Wednesday, March 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

inkl

Read news from The Economist, FT, and more,
with one subscription

Vertex Energy Stock Skyrockets After Q4 Results; Expects To Close Mobile Refinery Deal As Planned

Vertex Energy Stock Skyrockets After Q4 Results; Expects To Close Mobile Refinery Deal As Planned

Vertex Energy Inc (NASDAQ:VTNR) reported fourth-quarter revenue growth of 82.5% year-over-year to $31.79 million, beating the consensus of $29.37 million. Q4 Adjusted net income recovered to $4.64 million from a loss of $(2.74) million in 4Q20. The gross margin declined by 130 bps to 1%. The company reported an operating loss of $(7.46)…

Vertex Earnings Preview

Vertex Earnings Preview

Vertex (NASDAQ:VERX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement. Analysts estimate that Vertex will report an earnings per share (EPS) of $0.05.

Vectrus Agrees To Merge With Vertex

Vectrus Agrees To Merge With Vertex

Vectrus Inc (NYSE:VEC) entered a definitive agreement to combine with The Vertex Company in an all-stock merger. Vertex Company is headquartered in Madison, Mississippi, and employs ~6,000 employees. Vertex is majority-owned by American Industrial Partners Capital Fund VI LP. Vertex delivers integrated turnkey lifecycle support from concept definition to engineering and manufacturing.…

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.

Vertex Pharmaceuticals Clocks 27% Growth In Product Revenues, Issues FY22 Guidance

Vertex Pharmaceuticals Clocks 27% Growth In Product Revenues, Issues FY22 Guidance

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) posted

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play